GlassScriptPhysician profile
Ryan John Dyess
NPI 1487017257
$2,138.88
in general payments reported to CMS, 2019-2025
14 companies · $836 in 2025
The $836 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.57 · 2022: $108 · 2023: $149 · 2024: $954 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,938.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $961.94 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $401.87 | 2022-2025 | Omnipod |
| Dexcom, INC. | $162.64 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Medtronic, INC. | $161.13 | 2025 | Minimed 780g |
| Novo Nordisk INC | $91.57 | 2019 | |
| Ascendis Pharma Endocrinology INC | $76.27 | 2023-2025 | Skytrofa |
| Beta Bionics, INC. | $54.49 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Abbvie INC. | $53.66 | 2023-2025 | Lupron Depot |
| Sanofi-Aventis U.S. LLC | $49.27 | 2024-2025 | |
| Kyowa Kirin, INC. | $28.30 | 2024 | Crysvita |
| Rhythm Pharmaceuticals, INC. | $27.91 | 2024 | Imcivree |
| Pfizer INC. | $26.68 | 2024 | |
| Amphastar Pharmaceuticals, INC. | $24.66 | 2025 | |
| Tolmar, INC. | $18.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Dyess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.